Immune Thrombocytopenia (ITP) is an autoimmune bleeding disorder. Tyrosine Kinase JAK2 (JAK2 V617F) mutation occurs in nearly 60% of Essential Thrombocythemia (ET) patients. Both diseases produce impaired platelet. We describe a case with ET following ITP. So far, only 3 reports described ET following ITP. We report the fourth patient with JAK2 V617F mutation at the onset of ITP presented 20 years ago that needed splenectomy. The association of these two diseases may recommend similar pathogenic mechanisms between Myeloproliferative Neoplasms (MPNs) and ITP that should be further explored.

**ABSTRACT**

Immune Thrombocytopenia (ITP) is an autoimmune bleeding disorder. Tyrosine Kinase JAK2 (JAK2 V617F) mutation occurs in nearly 60% of Essential Thrombocythemia (ET) patients. Both diseases produce impaired platelet. We describe a case with ET following ITP. So far, only 3 reports described ET following ITP. We report the fourth patient with JAK2 V617F mutation at the onset of ITP presented 20 years ago that needed splenectomy. The association of these two diseases may recommend similar pathogenic mechanisms between Myeloproliferative Neoplasms (MPNs) and ITP that should be further explored.
Introduction

The JAK2 gene is a cytoplasmic tyrosine kinase that plays a role in cellular signaling of several hematopoietic growth factors, and differentiation, proliferation, and self-regeneration of stem cells [1]. The mutation in this gene directly affects the coding sequence of JAK2 and activates the JAK-STAT pathway; thus, disrupting the function of the hematopoietic stem cells is associated with hematopoiesis [2, 3]. The JAK2 V617F is a base substitution mutation that has been identified in Philadelphia-negative Myeloproliferative Neoplasms (Ph-MPNs), such as Primary Myelofibrosis (PMF), Polycythemia Vera (PV), and Essential Thrombocytosis (ET) [4] and has been found in about 50% of ET patients [5, 6].

ET is the expansion of clonal hematopoietic stem cells and is characterized by continuous clonal thrombosis, excessive megakaryocyte expansion in bone marrow, increased platelet count, usual erythrocytic mass, and the lack of prominent bone marrow fibrosis. Because the ET and other Ph-negative MPNs have common clinical and biological symptoms that make them difficult to diagnose, it is very important to use molecular techniques to classify the clinical and pathophysiological features of these diseases [2, 5].

Immunotrombocytopenia (ITP) is an acquired autoimmune disease characterized by platelet destruction and suppression of the production of megakaryocyte platelet [7, 8]. In this hematologic disorder that is identified by mild or severe thrombocytopenia, the platelet count is less than 100 G/L, leading to the manifestation of a hemorrhagic disorder [9, 10]. The most important symptoms of this disease include petechia, mucosal bleeding, ecchymosis, and purpura [11]. The incidence of ITP is 1 to 13 per 100,000 people and may occur at any age [12]. ET and ITP are two different blood disorders that highly affect the number of platelets. So far, only three cases with ET following ITP have been reported. Limited data are available on two types of platelet disorders that occur in succession. In this study, we report the fourth case of the diagnosed ET, 19 years after the diagnosis of ITP.

Case Presentation

In May 1999, an 18-year-old single female patient presented with a complaint of mucosal bleeding with petechiae, epistaxis, ecchymosis, and Platelet (PLT) count of 10,000/μL that had been diagnosed with ITP. Hemoglobin (Hb), White Blood Cell count (WBC), and coagulation tests were normal. All tests for Cytomegalovirus (CMV), hepatitis B and C, and HIV were negative. Bone marrow aspirate indicated increased myeloid/erythroid ratio and megakaryocytes. Treatment had been initiated with daily prednisone (1 mg/kg) with proper PLT response (161,000 / μl), but after tapering, the platelet decreased significantly. Due to poor tolerance and efficacy, in June 2000, splenectomy was performed and her platelet count reached normal (372,000/μl). Over the following 19 years, no close follow-up has been considered for the patient and in January 2019, she (age 39) was again referred to our clinic by her general practitioner because of a PLT count of 689,000/μL (Figure 1). A bone marrow trephine indicated increased myeloid/erythroid ratio and megakaryocytes. Treatment had been initiated with daily prednisone (1 mg/kg) with proper PLT response (161,000 / μl), but after tapering, the platelet decreased significantly. Due to poor tolerance and efficacy, in June 2000, splenectomy was performed and her platelet count reached normal (372,000/μl). Over the following 19 years, no close follow-up has been considered for the patient and in January 2019, she (age 39) was again referred to our clinic by her general practitioner because of a PLT count of 689,000/μL (Figure 1). A bone marrow trephine indicated increased cellularity and clustering of large and giant mature megakaryocytes with folded nuclei. A real-time Polymerase Chain Reaction (real-time PCR) analysis revealed the presence of JAK2 V617F mutation in her peripheral blood.

The patient was diagnosed with ET based on the World Health Organization (WHO) 2008 criteria [13],

Figure 1. Platelet count over the follow-up of the patient with Immune Thrombocytopenia (ITP) and Essential Thrombocytemia (ET)
treating with Hydroxyurea (HU; 500 mg) daily in divided doses. PLT count reached the normal range in July 2019. Presently, the patient does not have the side effects on a similar dosage of HU. Patient characteristics are summarized in Table 1.

Discussion

The discovery of the mutation in the JAK2 gene made significant advances in understanding the pathophysiology of Ph-negative myeloproliferative neoplasms. The JAK2 V617F mutation, which is restricted to blood cells and causes specific phosphorylation along with triggering of the tyrosine kinase function, has been proposed as a beneficial molecular marker in the detection of MPNs [14]. Researchers have found that mutations in this gene can be detected in approximately 0.2% of adult patients with no hematological disorder [15]. In this study, we examined a case, for whom ITP and ET were detected in the gap of 19 years. These two diseases have different clinical symptoms and the intrinsic relationship between them is complex, but according to the results of a population-based study, a 20% increase in the risk of developing MPN is observed in cases with a history of autoimmune diseases, such as ITP [16]. Also, a study by Sobas et al. on a 45-year-old woman suggested the association between autoimmune disorders and the JAK/STAT signaling pathway, and it was introduced as a potential factor for neoplastic ET progression in women with a history of ITP [8]. Huang et al. reported a JAK2-positive patient with a small MPN clone caused by low JAK2 allele burden, which was related to thrombocytosis and leukocytosis after splenectomy, and thrombocytosis was probably covered due to cellular destruction by immunity in the spleen pre-splenectomy [17]. Firstly, Caocci et al. investigated the JAK2 allele burden at the onset of ITP, which resulted in a small 3% JAK2-positive clone at the beginning of ITP diagnosis, which increased to 27% in the 13 next years. In this case, a splenectomy was performed on the patient, followed by progressive thrombocytosis [18]. Finally, in our case, who was a JAK2-positive patient, we faced thrombocytosis after splenectomy. It can be concluded that the interaction between autoimmune disorders and MPNs is a complex issue that needs further investigation.

Conclusion

In conclusion, it can be speculated that splenectomy and autoimmunity may influence the development of the JAK2 V617F mutation and MPNs; thus, analysis of this mutation could be suggested to ITP patients.

Ethical Considerations

Compliance with ethical guidelines

All ethical principles are considered in this article. The participants were informed of the purpose of the research and its implementation stages. They were also assured about the confidentiality of their information. They were free to leave the study whenever they wished, and if desired, the research results would be available to them. Written consent has been obtained from the subjects. principles of the Helsinki Convention was also observed.

Funding

This research did not receive any grant from funding agencies in the public, commercial, or non-profit sectors.

Conflict of interest

The authors declared no conflicts of interest.

Table 1. Information of the reported case with Immune Thrombocytopenia (ITP) and Essential Thrombocythemia (ET)

| Variables       | Sex        | Female |
|-----------------|------------|--------|
| ITP Diagnosis   | May 1999 (age: 18, y) |
| ITP Treatment   | Prednisone, Splenectomy |
| ET Diagnosis    | January 2019 (age: 18-39, y) |
| JAK2 Mutation   | Positive |
| Splenomegaly    | Yes |
| ET Treatment    | Hydroxyurea |
References

[1] Singdong R, Srirboonpiputtana T, Chareonsrisuthigul T, Kongruang A, Limsuwanachat N, Sirirat T, et al. Characterization and prognosis significance of JAK2 (V617F), MPL, and CALR mutations in Philadelphia-negative myeloproliferative neoplasms. Asian Pacific Journal of Cancer Prevention. 2016; 17(10):4647-53. [DOI:10.22034/apjcp.2016.10.4647] [PMID] [PMCID]

[2] Dos Santos LC, Ribeiro JC, Silva NP, Cerutti J, da Silva MR, de Lourdes Lopes Ferrari, Chauffaille M. Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia. Revista Brasileira de Hematologia e Hemoterapia. 2011; 33(6):417-24. [DOI:10.5581/1516-8484.20110116] [PMID] [PMCID]

[3] Rampal R, Al-Shahrour F, Abdel-Wahab O, Patel JP, Brunel JP, Merrem CH, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014; 123(22):e123-33. [DOI:10.1182/blood-2014-02-554634] [PMID] [PMCID]

[4] Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005; 7(4):387-97. [DOI:10.1016/j.ccr.2005.03.023] [PMID]

[5] Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: Interaction with treatment, standard risk factors, and Jak2 mutation status. Blood. 2007; 109(6):2310-3. [DOI:10.1182/blood-2006-09-046342] [PMID]

[6] Schafer AI. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood. 2006; 107(11):4214-22. [DOI:10.1182/blood-2005-08-3526] [PMID]

[7] Gernsheimer T. Chron ic idiopathic thrombocytopenic purpura: Mechanisms of pathogenesis. The Oncologist. 2009; 14(1):12-21. [DOI:10.1634/theoncologist.2008-0132] [PMID]

[8] Sobas MA, Wróbel T, Zduniak K, Podolak-Dawidziak M, Rybka J, Biedroń M, et al. Immune thrombocytopenia and JAK2V617F positive essential thrombocythemia: Literature review and case report. Case Reports in Hematology. 2017; 2017:3725089. [DOI:10.1155/2017/3725089] [PMID] [PMCID]

[9] Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood. 2009; 113(11):2386-93. [DOI:10.1182/blood-2008-07-162503] [PMID]

[10] Agarwal S, Jajodia N, Laksmi S, Kandpal P. Idiopathic Thrombocytopenic Purpura (ITP): A case report. International Healthcare Research Journal. 2017; 3(10):315-9. [DOI:10.26440/IHR/01_10/137]

[11] Shan NN, Zhu XJ, Peng J, Qin P, Zhuang XW, Wang HC, et al. Interleukin 18 and interleukin 18 binding protein in patients with idiopathic thrombocytopenic purpura. British Journal of Haematology. 2009; 144(5):755-61. [DOI:10.1111/j.1365-2141.2008.07520.x] [PMID]

[12] George JN. Thrombocytopenia due to enhanced platelet destruction by immunologic mechanisms. New York: Williams Hematology; 1995. https://ci.nii.ac.jp/naid/10029533888/ [PMID]

[13] Thiele J, Kvansnicka HM. The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Current Hematologic Malignancy Reports. 2009; 4(1):33-40. [DOI:10.1007/s11899-009-0005-6] [PMID]